Regulatory submissions on track for BioMarin's GALNS

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said during its R&D day on Thursday that it remains on track to submit regulatory applications next quarter in the U.S. and EU for Vimizim elosulfase alfa (formerly GALNS) to treat mucopolysaccharidosis IVA (MPS-IVA, Morquio's syndrome). BioMarin said the recombinant human N-acetylgalactosamine-6-sulfatase, which it plans to price between $250,000-$400,000 per year, could potentially double the company's revenues. BioMarin said it estimates that there are about 3,000 eligible patients worldwide. ...